Protective Effects of Recombinant Human Erythropoietin ... - Core

S98 Conclusion: Mito-TEMPO could restore mitochondrial function and dissociating TXNIP from NLRP3 to inhibit NLRP3 inflammasome activation. TXNIP siRNA also decreased NLRP3 activation significantly in HK2 cells during oxygen-glucose deprivation injury.

http://dx.doi.org/10.1016/j.hkjn.2015.09.067

0209 Sirolimus Attenuates Renal IschemiaeReperfusion Injury and Subsequent Regeneration of Tubular Epithelial Cells in a Rat Model

Acute Kidney Injury vs. 23.6 17.9 days. All-cause mortality was significantly lower in CA-AKI group compared to HA-AKI group, 11.9% vs. 20.5%. Results by multivariate logistic regression model analysis demonstrated the common independent risk factors of AKI in both groups were ICU hospitalization and shock. The independent risk factor of AKI in CA-AKI group was diabetes (OR Z 2.323). In contrast, the independent risk factors of AKI in HA-AKI group were elderly (OR Z 3.303), oliguria (OR Z 6.906), use of anti-inflammatory drugs (OR Z 13.079) and multiple organ dysfunction syndrome (OR Z 17.778). Conclusion: Present study revealed majority AKI either community-acquired or hospital-acquired were caused by pre-renal etiologies. All-cause mortality was lower in community-acquired AKI compared to hospital-acquired AKI. The independent risk factors were different between CA-AKI and HA-AKI.

Zhigang Wang, Baoping Chen Huaihe Affiliated Hospital of Henan University, Kaifeng, Henan, China Objective: To evaluate the attenuation of renal ischemiaereperfusion (I/R) injury and subsequent regeneration of tubular epithelial cells with sirolimus treatment in a rat model. Methods: Ninety male rats were randomized into five groups of 18 rats each: a sham group, a control group (I/R without immunosuppression), and three sirolimus treatment groups (I/R with pre- and postoperative sirolimus treatment, via gastric gavage, at 1, 3, and 5 mg/kg/d in respective groups). I/R injury was induced by occlusion (for 45 minutes) and reperfusion of the left renal artery, the right kidney was removed upon reperfusion of the left renal artery. Levels of sirolimus, serum creatinine, b2-microglobulin (b2-MG), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18 (IL-18), and hepatocyte growth factor (HGF) were assessed from blood samples by ELISA; expression of Fas and Bcl-2, proliferating cell nuclear antigen (PCNA), HGF, bone morphogenetic protein-7 (BMP-7), as well as other indicators and rate of apoptosis were determined by immunohistochemical, Western blot, PCR, and TUNEL assays; and histopathologic changes were observed in H&E-stained sections of renal tissue for pathologic scoring. Results: Indicators of renal injury (serum creatinine, b2-MG, IL-18, Fas, and pathologic scoring) were lower in irolimus-treated groups (dose-dependent change) versus the control group at 1, 3, and 7 days after I/R injury as were indicators of tissue repair (HGF, Bcl-2, BMP-7, PCNA); however, Bcl-2 and NGAL levels were upregulated in the sirolimus-treated groups versus sham and control groups (P < 0.05 for all). Effects on apoptosis were marked in the group treated with the highest sirolimus dose (5 mg/kg/d) compared with the other four groups. Cell proliferation was lower in the treatment groups versus the control group. Conclusion: Sirolimus has dose-dependent renoprotective and antiapoptotic effects in early-stage I/R injury to the kidney; it can also downregulate repair of tubular epithelial cell by its effect on cell proliferation.


0226 Clinical Characteristics of Acute Kidney Injury in Community-acquired and Hospital-acquired Patients in Xinjiang Suhua Li, Mingming Qiao, Shun Wang, Caichang Li, Li Zhang, Jian Liu The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China Objective: The aim of present study was to compare clinical characteristics between community-acquired acute kidney injury (CA-AKI) and hospital-acquired acute kidney injury (HA-AKI) patients in Xinjiang. Methods: The study used the hospital network system to screen the clinical data on adult patients in the First Affiliated Hospital in Xinjiang Medical University from January to July 2013. A total 19,528 patients were screened, 544 AKI patients were enrolled based on KIDGO AKI guidelines. 330 patients were included in HA-AKI group and 214 patients in CA-AKI group. Clinical variables including mortality were analyzed retrospectively. Results: The mean age in CA-AKI group was significantly older than HA-AKI group, 62.9 16.8 years vs. 56.6 15.9 years. The incidence of AKI in hospitalized patients was 2.8% (544/19,528), among them, CA-AKI group was 1.7% and HA-AKI group was 1.1%. The comorbid diseases were cardiac disease, hypertension, diabetes and chronic liver disease. The majority of AKI was caused by pre-renal etiologies including acute blood loss, low plasma volume, and low cardiac output. The length of hospitalized days was significantly shorter in CA-AKI group compared to HA-AKI group, 16.7 15.1 days


0233 Protective Effects of Recombinant Human Erythropoietin Combined with Alprostadil in Treatment of Acute Kidney Injury Bin Liu, Y. L. Sun Affiliated Calmette Hospital of Kunming Medical University, Kunming, Yunnan, China Objective: To investigate the protective effects of recombinant human erythropoietin (rHuEPO) combined with alprostadil in treatment of acute kidney injury (AKI). Methods: A total of 120 hospitalized patients in June 2009 to October 2013 with AKI were randomly divided into four groups: control groupdhemodialysis (HD) treatment; rHuEPO groupdHD with rHuEPO (3000 u, tiw); alprostadil groupdHD with alprostadil (20 ug, qd); combined treatment groupdHD, rHuEP (3000 u, tiw) and alprostadil (20 ug, qd), using medicine for 14 days. Recording theoliguric stage, checking serum creatinine and urinary NGAL/IL18 at 4, 8 and 15 days. Results: (1) The combined treatment group of oliguric stage is the shortest (5 0.8 days) compared with the other three groups (P < 0.05). With the extension of treatment time each Scr declined, the combined treatment group is the most obvious, with control group has statistically significant difference (P < 0.05). (2) The urine NGAL of the control group was higher than the other three groups (P < 0.05). EPO group and alprostadil group were close, but were higher than the combined treatment group, with statistically significant difference (P < 0.05). The urine IL-18 of the control group was higher than in the other three groups (P < 0.05). Conclusion: rHuEPO and alprostadilin treatment of acute kidney injury is effective. rHuEPO combined with alprostadil in treatment of acute kidney injury can shorten oliguric stage, improving renal function effectively.
